Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/437)
  • Patent number: 9487541
    Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 8, 2016
    Assignees: Purdue Research Foundation, National University Corporation Kumamoto University
    Inventors: Arun K. Ghosh, Chun-Xiao Xu, Hiroaki Mitsuya, Garth Parham
  • Patent number: 9114117
    Abstract: The present invention describes a Composition, comprising one or more compounds selected from the group consisting of a) compound (I) which is ethacrynic acid bezafibrate, fenofibrate, and/or griseofulvin, b) compound (II), which is ciclopirox ciclopirox olamine, octopirox, and/or cinnarizine, c) mixtures of compound (I) and compound (II), or pharmaceutically acceptable derivatives thereof for the treatment of cancer. The present invention is further directed to the use of said compounds or a mixture of compounds for the manufacture of a medicament for the treatment of cancer and to the use of said compound in a method for treating cancers in animals and humans.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: August 25, 2015
    Assignee: Ingo Schmidt-Wolf
    Inventor: Ingo Schmidt-Wolf
  • Patent number: 9000031
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: April 7, 2015
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Publication number: 20150087620
    Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 26, 2015
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
  • Patent number: 8846749
    Abstract: The present invention provides a novel xanthone derivative compound or a pharmaceutically acceptable salt thereof. The compound is useful as a chemosensitizer that reduces anticancer drug resistance.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: September 30, 2014
    Assignee: Ewha University-Industry Collaboration Foundation
    Inventors: Young Hwa Na, Young Joo Kwon, Hwa Jeong Lee, Song Wha Chae, Sang Wook Woo, Hee Ju Cho
  • Publication number: 20140256784
    Abstract: Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone.
    Type: Application
    Filed: May 21, 2014
    Publication date: September 11, 2014
    Inventors: Joseph BARBOSA, Kenneth Gordon CARSON, Michael Walter GARDYAN, Jason Patrick HEALY, Qiang HAN, Ross MABON, Praveen PABBA, James TARVER, JR., Kristen M. TERRANOVA, Ashok TUNOORI, Xiaolian XU
  • Publication number: 20140179754
    Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.
    Type: Application
    Filed: October 8, 2013
    Publication date: June 26, 2014
    Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, PURDUE RESEARCH FOUNDATION
    Inventors: Arun K. GHOSH, Chun-Xiao Xu, Hiroaki Mitsuya, Garth Parham
  • Publication number: 20140161731
    Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 12, 2014
    Applicant: WisTa Laboratories Ltd.
    Inventors: Scott Clunas, John Mervyn David Storey, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Claude Michel Wischik
  • Publication number: 20140154319
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: June 21, 2013
    Publication date: June 5, 2014
    Inventors: Taehwan KWAK, Myung-Gyu Park
  • Patent number: 8729118
    Abstract: The present invention relates to the use of new and known dithiine derivatives for controlling unwanted microorganisms, more particularly phytopathogenic fungi, in crop protection, in the household and hygiene sector and in the protection of materials, and also to new dithiine derivatives, to processes for preparing them, to their use, and to crop protection compositions comprising these new dithiine derivatives.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: May 20, 2014
    Assignee: Bayer CropScience AG
    Inventors: Thomas Seitz, Jürgen Benting, Ulrike Wachendorff-Neumann
  • Patent number: 8703970
    Abstract: Disclosed herein are compounds having photoremovable protecting groups which are removed after the compounds absorbs light of a given wavelength and undergo an electrocyclic reaction between a chromophore in the compound attached via an anilide to a benzothiophene ring.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: April 22, 2014
    Assignee: Marquette University
    Inventors: Mark G. Steinmetz, Majher I. Sarker, Tasnuva Shahrin
  • Publication number: 20140105852
    Abstract: A process for making cross-linked polysaccharide gels, particularly cross-linked hyaluronic acid gels, under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications.
    Type: Application
    Filed: December 26, 2013
    Publication date: April 17, 2014
    Applicant: Ultraceuticals R&D Pty. Limited
    Inventors: Simone Charlotte Vonwiller, Geoffrey Kenneth Heber
  • Publication number: 20140106003
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Application
    Filed: August 6, 2013
    Publication date: April 17, 2014
    Applicant: SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Patent number: 8629177
    Abstract: Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids as a therapeutic. One embodiment of the present invention directed to the article of manufacture comprises a lyophilized particle or sphere having a diameter of about 100 to 500 nanometers having a shell and comprising a biodegradable polymer containing a cannabinoid. A featured cannabinoid is delta-9-tetrahydrocannabinol (delta-9-THC).
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: January 14, 2014
    Assignee: Aphios Corporation
    Inventors: Trevor Percival Castor, Geoffrey Purdum
  • Patent number: 8623907
    Abstract: Pyrandione, thiopyrandione and cyclohexanetrione derivatives of formula (I), which are suitable for use as herbicides.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: January 7, 2014
    Assignee: Syngenta Participations, AG
    Inventors: James Nicholas Scutt, Christopher John Mathews, Michel Muehlebach
  • Publication number: 20130338151
    Abstract: The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.
    Type: Application
    Filed: October 21, 2010
    Publication date: December 19, 2013
    Applicant: Fibrotech Therapeutics Pty Ltd
    Inventors: Spencer John Williams, Steven Zammit, Darren James Kelly
  • Publication number: 20130302422
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 14, 2013
    Applicants: KT & G CORPORATION, MAZENCE INC.
    Inventors: Taehwan Kwak, Myung-Gyu Park, Kyoung Hoon Jung
  • Patent number: 8563597
    Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Methods of using the disclosed compounds for treating patients infected with HIV are also described.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: October 22, 2013
    Assignees: Purdue Research Foundation, National University Corporation Kumamoto University
    Inventors: Arun K. Ghosh, Chun-Xiao Xu, Hiroaki Mitsuya, Garth Parham
  • Publication number: 20130243886
    Abstract: The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an a-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.
    Type: Application
    Filed: September 9, 2011
    Publication date: September 19, 2013
    Applicant: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony RM Coates
  • Patent number: 8524762
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: September 3, 2013
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Patent number: 8475776
    Abstract: Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: July 2, 2013
    Assignee: Paloma Pharmaceuticals, Inc.
    Inventor: David I. Sherris
  • Publication number: 20130158094
    Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.
    Type: Application
    Filed: September 2, 2011
    Publication date: June 20, 2013
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventors: Arun K. Ghosh, Chun-Xiao Xu, Hiroaki Mitsuya, Garth Parham
  • Patent number: 8410161
    Abstract: A thioxanthone ring system derivative compound is provided. The thioxanthone ring system derivative compound is represented by a formula (I): wherein X is a substituent being one selected from a group consisting of halogens, wherein R1 is a substituent being one selected from a group consisting of sulfur and sulfur dioxide, wherein R2 is a substituent being one selected from a group consisting of C1˜C10 alkyl group, C3˜C10 branched alkyl group, C3˜C10 cyclic alkyl group, phenyl group, phenyl alkyl group, and wherein hydrogen of phenyl group can be partially substituted by halogens, alkoxyl group, C1˜C10 alkyl group, nitro group or amine group.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: April 2, 2013
    Assignee: National Defense Medical Center
    Inventor: Hsu-Shan Huang
  • Patent number: 8404740
    Abstract: Spirocyclic cyclohexane compounds corresponding to formula I In which R1, R2, R3 and R5 through R10 and X have defined meanings, a process for their preparation, pharmaceutical compositions containing such compounds, and the use of such spirocyclic cyclohexane compounds in the treatment and/or inhibition of pain and other conditions mediated by the ORL-1 or the ?-opioid receptor.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: March 26, 2013
    Assignee: Gruenenthal GmbH
    Inventors: Stefan Schunk, Saskia Zemolka, Derek Saunders, Michael Gruss, Heinz Graubaum
  • Patent number: 8383617
    Abstract: A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: February 26, 2013
    Assignee: PAD Pharma Limited
    Inventors: Stuart Mark Wilson, Christopher John Stanley
  • Publication number: 20120322792
    Abstract: The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy.
    Type: Application
    Filed: January 11, 2012
    Publication date: December 20, 2012
    Applicant: MOUNT SINAI SCHOOL OF MEDICINE
    Inventors: Goutham Narla, Michael Ohlmeyer, Matthew David Galsky
  • Publication number: 20120302562
    Abstract: Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone.
    Type: Application
    Filed: May 23, 2012
    Publication date: November 29, 2012
    Inventors: Joseph BARBOSA, Kenneth Gordon CARSON, Michael Walter GARDYAN, Jason Patrick HEALY, Qiang HAN, Ross MABON, Praveen PABBA, James TARVER, JR., Kristen M. TERRANOVA, Ashok TUNOORI, Xiaolian XU
  • Publication number: 20120289577
    Abstract: The present invention relates to a composition for treating or preventing hearing loss comprising naphthoquinone-based compounds.
    Type: Application
    Filed: December 27, 2010
    Publication date: November 15, 2012
    Applicant: KT&G LIFE SCIENCES CORPORATION
    Inventors: Tae Hwan Kwak, Myung-Gyu Park, Hong-Seob So, Raekil Park, Hyung-Jin Kim
  • Publication number: 20120270863
    Abstract: The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 25, 2012
    Applicant: Fibrotech Therapeutics Pty Ltd
    Inventors: Spencer John Williams, Steven Zammit, Darren James Kelly
  • Patent number: 8236791
    Abstract: Provided are methods of determining whether a compound is an inhibitor of an S100 protein. The methods utilize a biosensor that comprises the S100 protein that has a covalently bound fluorescent dye at an amino acid residue of the S100 protein that becomes less exposed to the aqueous solution upon activation of the S100 protein, where the fluorescent dye has decreased fluorescence when exposed to the aqueous solution than when protected from exposure to the aqueous solution. Also provided are methods of treating a subject having metastatic cancer.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: August 7, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Anne Reba Bresnick, Sarah Claire Garrett
  • Publication number: 20120190724
    Abstract: The present invention provides a novel xanthone derivative compound or a pharmaceutically acceptable salt thereof. The compound is useful as a chemosensitizer that reduces anticancer drug resistance.
    Type: Application
    Filed: August 19, 2010
    Publication date: July 26, 2012
    Applicant: EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION
    Inventors: Young Hwa Na, Young Joo Kwon, Hwa Jeong Lee, Song Wha Chae, Sang Wook Woo, Hee Ju Cho
  • Patent number: 8178577
    Abstract: The present invention relates to certain tricyclic derivatives which are capable of inhibiting histone deacetylases. The compounds of this invention are therefore useful in treating diseases associated with abnormal histone deacetylase activities. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing these compounds are also disclosed.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: May 15, 2012
    Assignee: Shenzhen Chipscreen Biosciences Ltd.
    Inventors: Xian-Ping Lu, Zhi-Bin Li, Zhi-Qiang Ning
  • Publication number: 20120114714
    Abstract: Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 10, 2012
    Inventors: Taehwan KWAK, Myung-Gyu Park, Sang-Ku You
  • Patent number: 8158674
    Abstract: Provided are chalcogenoxanthylium compounds which can effectively be used as sensitizers in photodynamic therapy, virucides in photodynamic antimicrobial chemotherapy and reversal agents of Pgp function in cancer cells. Further provided is a general method for the preparation of chalcogenoxanthylium compounds.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: April 17, 2012
    Assignee: The Research Foundation of State University of New York
    Inventors: Michael R. Detty, David J. Donnelly
  • Publication number: 20120088810
    Abstract: A thioxanthone ring system derivative compound is provided. The thioxanthone ring system derivative compound is represented by a formula (I): wherein X is a substituent being one selected from a group consisting of halogens, wherein R1 is a substituent being one selected from a group consisting of sulfur and sulfur dioxide, wherein R2 is a substituent being one selected from a group consisting of C1˜C10 alkyl group, C3˜C10 branched alkyl group, C3˜C10 cyclic alkyl group, phenyl group, phenyl alkyl group, and wherein hydrogen of phenyl group can be partially substituted by halogens, alkoxyl group, C1˜C10 alkyl group, nitro group or amine group.
    Type: Application
    Filed: June 6, 2011
    Publication date: April 12, 2012
    Applicant: NATIONAL DEFENSE MEDICAL CENTER
    Inventor: Hsu-Shan HUANG
  • Publication number: 20110300074
    Abstract: This invention pertains generally to processes, uses, methods and materials utilising particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.
    Type: Application
    Filed: December 10, 2009
    Publication date: December 8, 2011
    Inventors: Scott Clunas, John Mervyn David Storey, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Claude Michel Wischik
  • Publication number: 20110275696
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Application
    Filed: March 8, 2011
    Publication date: November 10, 2011
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Publication number: 20110275645
    Abstract: The invention provides compounds that inhibit protein kinases, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and/or prodrugs, pharmaceutical compositions including the compounds and/or prodrugs and methods of using the compounds and/or prodrugs in a variety of contexts, including, for example, in the treatment and/or prevention of various diseases that are responsive to protein kinase inhibition and/or that are mediated, at least in part, by inappropriate kinase activity.
    Type: Application
    Filed: May 5, 2010
    Publication date: November 10, 2011
    Inventors: Renee Desai, Ketan Desai
  • Publication number: 20110256510
    Abstract: Disclosed are compositions and methods of using such compositions for inhibiting matrix metalloproteinase activity in dental tissue. The compositions, methods and uses may prevent degradation of the bonding between restorative materials and dental tissues, thereby increasing durability and longevity of the restorative material-dental tissue bonds. For example, the compositions, methods, and uses of the present invention may be used for treating carious dental tissue such as by the creation of dental fillings, crowns, bridges, among other techniques, as well as the creation of esthetic laminate restorations.
    Type: Application
    Filed: January 11, 2010
    Publication date: October 20, 2011
    Inventors: David Henry Pashley, Franklin Chin-Meng Tay, Milena Cadenaro
  • Patent number: 7998541
    Abstract: The present invention relates to benzochromene derivatives of the formula I where the various parameters have the meaning indicated in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in TN, OCB, LCOS and/or IPS-LCDs, and to the use of the compounds and physiologically acceptable derivatives thereof as therapeutic active ingredients.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: August 16, 2011
    Assignee: Merck Patent GmbH
    Inventors: Andreas Taugerbeck, Elvira Montenegro, Atsutaka Manabe, Herbert Plach
  • Publication number: 20110158983
    Abstract: In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.
    Type: Application
    Filed: March 5, 2009
    Publication date: June 30, 2011
    Inventors: Newell Bascomb, John Maki, Fredric S. Young
  • Publication number: 20110002995
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: January 6, 2011
    Applicants: MAZENCE INC., KT & G CORPORATION
    Inventors: Taehwan Kwak, Myung-Gyu Park
  • Publication number: 20100310657
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: December 9, 2010
    Applicants: MAZENCE INC., KT & G CORPORATION
    Inventors: Taehwan Kwak, Myung-Gyu Park, Kyoung Hoon Jung
  • Publication number: 20100285139
    Abstract: A pharmaceutical composition for prophylaxis and/or treatment of infections and/or infectious diseases occurring in cystic fibrosis includes at least one antidepressant; at least one dispersant; and at least one pharmaceutically tolerable carrier material.
    Type: Application
    Filed: December 22, 2008
    Publication date: November 11, 2010
    Applicant: CYCNAD GMBH & CO., KG
    Inventor: Erich Gulbins
  • Publication number: 20100255054
    Abstract: Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
    Type: Application
    Filed: November 26, 2007
    Publication date: October 7, 2010
    Inventors: Taehwan Kwak, Sang-ku Yoo, Myung-gyu Park
  • Publication number: 20100239685
    Abstract: Provided is a naphthoquinone-based compound represented by Formula 1 or 2 having therapeutic effect on the treatment and/or prevention of prostate and/or testicle (seminal glands)-related diseases, and to a pharmaceutical composition of intestinal delivery system containing the same.
    Type: Application
    Filed: November 26, 2007
    Publication date: September 23, 2010
    Inventors: Taehwan Kwak, Sang-Ku Yoo, Myung-gyu Park
  • Publication number: 20100239674
    Abstract: Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
    Type: Application
    Filed: November 26, 2007
    Publication date: September 23, 2010
    Inventors: Taehwan Kwak, Myung-gyu Park, Sang-Ku You
  • Publication number: 20100233244
    Abstract: The present invention relates to a quickly decomposing oral drug preparation, for the application of active ingredient combinations for smoking withdrawal, which contains nicotine, a nicotine salt, a nicotine derivative, or a substance that reacts to nicotine, in combination with another active ingredient, and the use of such a drug preparation for the treatment of smoking withdrawal, and the use of nicotine, and/or nicotine salts or derivatives, for the production of medications for the treatment of smoking withdrawal. The active ingredient that is to be administered, in combination, for this purpose is a centrally active ingredient, preferably an antidepressant for the fighting of psychic dependency in terms of a smoking withdrawal therapy. The administration of the active ingredient combination to the patient should be handled in a simple and reliable way and should exclude side effects to a large extent.
    Type: Application
    Filed: June 4, 2007
    Publication date: September 16, 2010
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Hans-Rainer Hoffmann, Reto Brändli, Frank Theobald
  • Publication number: 20100215635
    Abstract: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds alone or in combination with alkaline phosphatase or other weight loss-inducing drugs or methods to reduce or reverse excess weight gain and obesity as well as reduce the risk of development and help treatment of diseases and unhealthy conditions related to overweight and obesity.
    Type: Application
    Filed: February 23, 2009
    Publication date: August 26, 2010
    Inventor: Zoltan Kiss
  • Publication number: 20100216776
    Abstract: Provided are methods of determining whether a compound is an inhibitor of an S100 protein. The methods utilize a biosensor that comprises the S100 protein that has a covalently bound fluorescent dye at an amino acid residue of the S100 protein that becomes less exposed to the aqueous solution upon activation of the S100 protein, where the fluorescent dye has decreased fluorescence when exposed to the aqueous solution than when protected from exposure to the aqueous solution. Also provided are methods of treating a subject having metastatic cancer.
    Type: Application
    Filed: August 10, 2006
    Publication date: August 26, 2010
    Inventors: Anne Reba Bresnick, Sarah Claire Garrett